aprepitant oral / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 156 Diseases   15 Trials   15 Trials   235 News 


1234»
  • ||||||||||  aprepitant oral / Generic mfg.
    Patient reported outcomes with use of orally administered aprepitant in highly and moderately emetogenic (HEC and MEC) regimens (Exhibition area) -  Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_879;    
    Background NK-1 receptor antagonist aprepitant orally is given over 3 days in HEC and MEC regimens...Though administration of aprepitant provides 100% control of nausea and vomiting, real world practice data suggests otherwise. With narrowing gap in the costs of oral and i.v formulations of aprepitant, the latter must be preferred in HEC and MEC regimens to improve quality of chemotherapy delivery.
  • ||||||||||  pramipexole ER (CTC-413) / Chase Therap
    Trial completion date, Trial primary completion date:  A Study to Evaluate in Patients With Parkinsonian Type Disorders (clinicaltrials.gov) -  Jul 10, 2024   
    P2,  N=24, Active, not recruiting, 
    The mean age of overall group was 51.1 Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025
  • ||||||||||  pramipexole ER (CTC-413) / Chase Therap
    Trial completion date, Trial primary completion date:  A Study to Evaluate in Patients With Parkinsonian Type Disorders (clinicaltrials.gov) -  Oct 10, 2023   
    P2,  N=24, Active, not recruiting, 
    Aprepitant significantly improves emesis control in children receiving induction therapy for AML, especially in acute phase and should be routinely incorporated as part of antiemetic prophylaxis. Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
  • ||||||||||  pramipexole ER (CTC-413) / Chase Therap
    Enrollment closed, Trial completion date, Trial primary completion date:  A Study to Evaluate in Patients With Parkinsonian Type Disorders (clinicaltrials.gov) -  Feb 10, 2023   
    P2,  N=24, Active, not recruiting, 
    In contrast, plasma free ND-AP but not aprepitant was related to the antiemetic efficacy of oral aprepitant. Unknown status --> Active, not recruiting | Trial completion date: Mar 2020 --> Dec 2023 | Trial primary completion date: Dec 2019 --> Dec 2023
  • ||||||||||  melphalan / Generic mfg., olanzapine / Generic mfg.
    Trial completion, Trial completion date, Trial primary completion date:  Aprepitant- and Olanzapine- Containing Anti-emetic Regimens With High Dose Melphalan (clinicaltrials.gov) -  Dec 21, 2022   
    P3,  N=429, Completed, 
    Unknown status --> Active, not recruiting | Trial completion date: Mar 2020 --> Dec 2023 | Trial primary completion date: Dec 2019 --> Dec 2023 Unknown status --> Completed | Trial completion date: Nov 2020 --> Dec 2022 | Trial primary completion date: Nov 2020 --> Dec 2021
  • ||||||||||  dexamethasone / Generic mfg., mirtazapine / Generic mfg.
    Trial completion, Trial completion date, Trial primary completion date:  Adding Mirtazapine to Dexamethasone and Aprepitant for Delayed Emesis (clinicaltrials.gov) -  Apr 20, 2022   
    P3,  N=212, Completed, 
    Trial Registration: ClinicalTrials.gov identifier: NCT04013386. Recruiting --> Completed | Trial completion date: Dec 2019 --> Dec 2021 | Trial primary completion date: Dec 2019 --> Dec 2021
  • ||||||||||  aprepitant oral / Generic mfg.
    Preclinical, Journal:  Anti-nociceptive effects of dual neuropeptide antagonist therapy in mouse model of neuropathic and inflammatory pain. (Pubmed Central) -  Apr 1, 2022   
    The NK1 antagonist aprepitant (BIBN4096, 1 mg/kg) or the CGRP antagonist olcegepant (MK-0869, 10 mg/kg) was injected intraperitoneally...Isobolographic analysis showed a meaningful additive effect between the two compounds. A combination pharmacological therapy comprised of multiple neuropeptide antagonists could be a more effective therapeutic strategy for alleviating neuropathic or inflammatory pain.
  • ||||||||||  Trial completion date, Trial initiation date, Trial primary completion date:  Recommendations of Enhanced Recovery Interventions for Patient's Clinical Team and Collection of Associated Data (clinicaltrials.gov) -  Sep 13, 2021   
    P3,  N=35485, Not yet recruiting, 
    The present developed method showed an acceptable analytical performance and can be used to evaluate total and free aprepitant and its N-dealkylated metabolites in patient plasma. Trial completion date: Apr 2025 --> Dec 2025 | Initiation date: Sep 2021 --> Dec 2021 | Trial primary completion date: Apr 2024 --> Dec 2024
  • ||||||||||  hydroxyzine hydrochloride / Generic mfg.
    Trial completion date, Trial primary completion date:  APHYPAP: Aprepitant Versus Hydroxyzine in Persistent Aquagenic Pruritus for Patients With Myeloproliferative Neoplasms (clinicaltrials.gov) -  Jun 11, 2021   
    P3,  N=80, Recruiting, 
    The combination of aprepitant, dexamethasone and ondansetron failed to demonstrate a statistically significant superiority over the other two antiemetic regimens. Trial completion date: Nov 2020 --> Jan 2022 | Trial primary completion date: Sep 2020 --> Nov 2021
  • ||||||||||  ondansetron / Generic mfg., aprepitant oral / Generic mfg.
    Journal:  Highly effective use of aprepitant in an adolescent girl with severe cyclic vomiting syndrome. (Pubmed Central) -  May 15, 2021   
    She had a dramatic response to it, with no further episodes of vomiting since its start. There is an urgent need for randomised clinical studies to assess the efficacy of available treatment options, including aprepitant in patients with severe CVS.
  • ||||||||||  ketorolac / Generic mfg., promethazine / Generic mfg.
    [VIRTUAL] THE “ERAS” PROTOCOL REDUCES POST ENDOSCOPIC BARIATRIC PROCEDURE HEALTHCARE UTILIZATION (DDW Virtual) -  Mar 15, 2021 - Abstract #DDW2021DDW_4291;    
    Beginning in 2019, all patients received a standardized peri-procedure hydration, anti-emetic, and analgesic bundle consisting of intravenous fluids, dexamethasone, ondansentron, acetaminophen, ketorolac, pantoprazole, along with a scopolamine patch and oral aprepitant,the “Enhanced Recovery After Endoscopic ProcedureS” (ERAS) protocol as a quality improvement initiative...Implementation of a standardized ERAS protocol for endoscopic bariatric procedures with a structured post-procedure RN contact reduced overall healthcare utilization and hospital admissions, and decreased ED visits resulting in a hospital admission. Strategic ITC use may further decrease ED visits and hospitalization rates.
  • ||||||||||  Emend intravenous (fosaprepitant) / Merck (MSD), Novartis
    [VIRTUAL] Venous Irritation Resulting from IV Fosaprepitant: A Systematic Review of Evidence () -  Mar 12, 2021 - Abstract #ONS2021ONS_457;    
    Fosaprepitant-induced peripheral venous irritation (PVI) among patients receiving certain chemotherapy regimens, particularly Adriamycin, leads to delays in treatment, wasted resources, additional medical intervention, and patient dissatisfaction...Commentary and tutorial articles suggest switching to oral aprepitant or administration via a central line, but do not cite clinical evidence to support these recommendations...Clinical trials are needed to determine the comparative effectiveness. When the results of those trials are available, guidelines should be updated to guide practice.
  • ||||||||||  Januvia (sitagliptin) / Merck (MSD)
    Trial completion:  Effect of Chronic ACE and DPP4 Inhibition on Blood Pressure (clinicaltrials.gov) -  Sep 2, 2020   
    P=N/A,  N=107, Completed, 
    The use of the oral NK1 inhibitor aprepitant in combination with oPac+E is not recommended.(NTC02594371) Recruiting --> Completed
  • ||||||||||  olanzapine / Generic mfg.
    Trial completion, Enrollment change:  FORESIGHT: Feasibility of Olanzapine at REduced doSe in hIGHly Emetogenic chemoTherapy (clinicaltrials.gov) -  Aug 19, 2020   
    P3,  N=30, Completed, 
    The developed population PK model adequately described aprepitant PK across a broad pediatric population, justifying fixed (adult) dosing for adolescents and weight-based dosing of oral aprepitant for children. Recruiting --> Completed | N=60 --> 30
  • ||||||||||  olanzapine / Generic mfg.
    Trial completion date, Trial primary completion date:  Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Chinese Breast Cancer Patients (clinicaltrials.gov) -  Jul 10, 2020   
    P3,  N=120, Active, not recruiting, 
    Perphenazine can be considered a cost effective alternative as there was no significant difference in the effectiveness for oral aprepitant or perphenazine for prophylaxis of PONV in patients undergoing CRS within an ERP. Trial completion date: Dec 2020 --> Dec 2022 | Trial primary completion date: Dec 2020 --> Dec 2022